Biological evaluation of Tyr6 and Ser7 modified drosocin analogues

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 11, 2005, Pages 2902-2905

  De Visser, Peter C ^a,b   Van Hooft, Peter A V ^a   De Vries, Anne Marij ^a   De Jong, Ad ^a   Van Der Marel, Gijsbert A ^b   Overkleeft, Herman S ^b   Noort, Daan ^a  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DROSOCIN; SERINE; TYROSINE;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; NONHUMAN; PROTEIN DEGRADATION;

AMINO ACID SEQUENCE; GLYCOPEPTIDES; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; SERINE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TYROSINE;

EID: 19644387520     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.03.074     Document Type: Article

References (21)

1. M. Cudic, C.V. Lockatell, D.E. Johnson, and L. Otvos Jr. Peptides 24 2003 807
2. For selected reviews, see: L. Otvos Jr. Cell. Mol. Life Sci. 59 2002 1138
3. L. Otvos Jr. J. Peptide Sci. 6 2000 497
4. Y.-T. Tan, D.J. Tillett, and I.A. McKay Mol. Med. Today 6 2000 309
5. M.G. Scott, and R.E.W. Hancock Crit. Rev. Immunol. 20 2000 407
6. R.E.W. Hancock, and D.S. Chapple Antimicrob. Agents Chemother. 43 1999 1317
7. For example, see: K.A. Brogden, M. Ackermann, P.B. McCray Jr., and B.F. Tack Int. J. Antimicrob. Agents 22 2003 465
8. M. Papagianni Biotechnol. Adv. 21 2003 465
9. R.E. Hancock, and A. Patrzykat Curr. Drug Targets Infect. Disord. 2 2002 79
10. R. Jerala, and M. Porro Curr. Top. Med. Chem. 4 2004 1173
11. P.C. de Visser, N.M.A.J. Kriek, P.A.V. van Hooft, A. Van Schepdael, D.V. Filippov, G.A. van der Marel, H.S. Overkleeft, J.H. van Boom, and D. Noort J. Peptide Res. 61 2003 298
12. P. Bulet, L. Urge, S. Ohresser, and L. Otvos Jr. Eur. J. Biochem. 238 1996 64
13. L. Otvos Jr., I. O, M.E. Rogers, P.J. Consolvo, B.A. Condie, S. Lovas, P. Bulet, and M. Blaszczyk-Thurin Biochemistry 39 2000 14150
14. P. Casteels, and P. Tempst Biochem. Biophys. Res. Commun. 300 1994 567
15. G. Kragol, S. Lovas, G. Varadi, B.A. Condie, R. Hoffmann, and L. Otvos Jr. Biochemistry 40 2001 3016
16. D. Wade, A. Boman, B. Wahlin, C.M. Drain, D. Andreu, H.G. Boman, and R.B. Merrifield Proc. Natl. Acad. Sci. U.S.A. 87 1990 4761
17. R. Hoffmann, P. Bulet, L. Urge, and L. Otvos Jr. Biochim. Biophys. Acta 1426 1999 459
18. L. Otvos Jr., K. Bokonyi, I. Varga, B.I. Otvos, R. Hoffmann, H.C.J. Ertl, J.D. Wade, A.M. McManus, D.J. Craik, and P. Bulet Protein Sci. 9 2000 742
19. G. Jou, I. González, F. Albericio, P. Lloyd-Williams, and E. Giralt J. Org. Chem. 62 1997 354
20. Only fragments with molecular weight of 800 or more were taken into consideration. The relative abundance of these fragments was calculated under the assumption that the detector sensitivity was uniform for all fragments
21. The following degradation products were also detected: -C1, N1 for analogue 7 (abundance 1), -C2, N5 for analogues 2, 6 and 9 (abundance 3, 1, and 1, respectively) and -N10 (abundance 2) for 16